BMO Capital analyst Jim Birchenough reiterated an Outperform rating and $159 price target on Gilead Sciences (NASDAQ: GILD) following "strong ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS View

Gilead Sciences (GILD) 'Crushed' the Quarter, Piper Jaffray Says; Remains Top Large-Cap Biotech PickMay 1, 2015 7:10 AM Gilead Sciences (GILD) Bullish Stance Reiterated at Baird on 'Beat and Raise' Q1May 1, 2015 6:42 AM Gilead Sciences (GILD) Tops Q1 EPS by 48c, Raises FY Revenue GuidanceApril 30, 2015 4:02 PM Gilead Sciences Declares First Quarterly Cash DividendApril 30, 2015 4:02 PM